Beta-cell function and metabolic control in insulin treated diabetics

Area of Science:

• Endocrinology
• Metabolic Diseases
• Diabetes Research

Background:

• Beta-cell dysfunction is central to type 1 diabetes pathogenesis.
• Assessing residual beta-cell function is crucial for understanding disease progression and treatment efficacy.
• Insulin therapy is standard for managing type 1 diabetes, but preserving endogenous insulin production remains a goal.

Purpose of the Study:

• To evaluate residual beta-cell function in insulin-treated diabetic patients.
• To determine the correlation between beta-cell function and metabolic control.
• To identify thresholds of beta-cell function associated with improved diabetes management.

Main Methods:

• A one-day study involving 210 insulin-treated diabetic patients.
• Measurement of serum C-peptide concentration 6 minutes after intravenous glucagon injection.
• Analysis of patient demographics, insulin dosage, 24-hour glycosuria, and fasting blood glucose levels.

Main Results:

• 31% of patients exhibited residual beta-cell function.
• Patients with residual function were younger at onset, had shorter disease duration, and received lower insulin doses.
• Residual beta-cell function correlated inversely with glycosuria and fasting blood glucose.
• Only patients with C-peptide levels >0.30 pmol/ml showed significantly better metabolic control.
• 24-hour glycosuria measurements may overestimate metabolic control in daily life.

Conclusions:

• Maintaining beta-cell function above 0.30 pmol/ml facilitates better metabolic control in insulin-treated diabetics.
• Residual beta-cell function is associated with specific patient characteristics and treatment parameters.
• Clinical assessments of glycosuria may not fully reflect real-world metabolic control.